Trials / Terminated
TerminatedNCT03065790
Early FDG PET/CT Imaging as a Measure of Response in Patients With Non-Hodgkin Lymphoma on Lenalidomide
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 1 (actual)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Adult patients with non-Hodgkin lymphoma who will be treated with lenalidomide will undergo FDG PET/CT scan as an early evaluation of response to therapy. Changes in FDG uptake will be correlated response and long term outcomes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | 2-Deoxy-2-[18F]fluoro-D-glucose (FDG) | 2-Deoxy-2-\[18F\]fluoro-D-glucose (FDG) |
Timeline
- Start date
- 2017-02-06
- Primary completion
- 2021-04-28
- Completion
- 2021-04-28
- First posted
- 2017-02-28
- Last updated
- 2021-06-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03065790. Inclusion in this directory is not an endorsement.